top of page

Alkermes Reports Positive Results

One of our Picks to Clicks for Q4 2016, Alkermes, announces positive topline results from its pivotal phase 3 study FORWARD-5 of ALKS 5461 for Major Depressive Disorder. See company press release. The stock was up over 25% on Friday. However, the stock could have been up more on this potential blockbuster drug, but investors are still worried that the FDA might not be convinced without another trial.


bottom of page